Immunomedics Earlier Announced $250M Royalty Funding And Stock Purchase Agreement With Royalty Pharma; Co. Has Sold Rights To Sacituzumab Govitecan To Royalty Pharma For $175M And Also Received $75M Equity Investment, Valuing Shares At $17.15/Share